Answers: measuring movement and functional outcomes

Gait is measured by recording how a person walks and reducing that walk to numbers. Three approaches account for most practice: timed walk tests using a stopwatch and a marked distance, instrumented walkways or body-worn sensors, and camera-based motion analysis. All three report spatiotemporal parameters such as walking speed, cadence, and stride length.

Spatiotemporal gait parameters are the distance and timing measures that describe a walking pattern: walking speed, cadence, step and stride length, step and stride time, stance and swing time, double support time, and step width. They are derived from when each foot contacts and leaves the ground, and from how far the body travels between those events.

Stance is the part of the gait cycle when a foot is in contact with the ground, roughly 60 percent of the cycle at usual walking pace. Measuring it means detecting two events per limb — initial contact and toe-off — and timing the interval between them. It is reported in seconds or as a percentage of the gait cycle, separately for each limb.

Gait speed is the distance a person walks divided by the time taken, reported in meters per second and usually measured at usual pace over a marked 4-meter or 10-meter course. It is used as an outcome because it is quick, reliable, and predicts mortality, disability, and hospitalization, which led to its description as the sixth vital sign.

Objective measures of functional outcome are performance-based measures: the patient performs a defined task and the result is timed, counted, or instrumented. Common examples are gait speed, the Timed Up and Go, sit-to-stand tests, the Short Physical Performance Battery, the six-minute walk test, and grip strength. They complement patient-reported outcomes, which record how the patient feels rather than what they can do.

Use gait speed when the question is walking capacity and prognosis, the Timed Up and Go when it involves transfers, turning, and dynamic balance together, and a sit-to-stand test when it is lower-limb strength and the ability to rise. They measure overlapping but distinct constructs, and many batteries include more than one for that reason.

Before surgery, patients with degenerative lumbar disease typically walk more slowly than matched controls, with shorter steps, reduced cadence, and longer stance and double support. Studies of decompression and fusion report improvements in walking speed, step and stride timing, pain-free walking distance, and sagittal trunk and pelvis alignment during walking, often measurable by three to six months.

Slowness is one of the five criteria in the Fried frailty phenotype, alongside weakness, exhaustion, low activity, and weight loss. Frailty is typically accompanied by slower walking, shorter steps, a wider base of support, longer double support time, and greater stride-to-stride variability. A usual-pace gait speed at or below 0.8 m/s is a widely used screening threshold.

Markerless motion capture estimates the positions of body landmarks directly from video using computer-vision pose estimation, with nothing attached to the body. A 2024 systematic review and meta-analysis reported good to excellent agreement with marker-based systems for spatiotemporal parameters and walking speed, with weaker agreement for joint angles outside the sagittal plane and at the ankle.

Yes, for spatiotemporal parameters. Peer-reviewed work has derived gait measures from ordinary two-dimensional video and from smartphone video using pose estimation, reporting close agreement with laboratory reference systems for measures such as walking speed and step length. Accuracy depends on camera placement, frame rate, spatial calibration, and an unobstructed view of the walking path.

Not for most clinical questions. Marker-based laboratory systems remain the reference standard for three-dimensional joint kinematics, but spatiotemporal measures such as walking speed, cadence, stride length, and stance timing can be obtained from timed walk tests, instrumented walkways, body-worn sensors, or camera-based analysis in ordinary space.

Choose the method from the endpoint rather than from what the technology can do. Define the construct, then select an instrument that is fit for purpose in the trial population, applies one identical protocol at every site, and produces auditable source data. FDA guidance asks sponsors to verify that a digital technology measures the parameter accurately and to validate that it assesses the intended clinical characteristic in that population.

Remote functional assessment replaces the site visit with participant-side capture — video recorded by the participant, a wearable, or a connected device — under a protocol that fixes the task, the environment, and the instructions. FDA guidance on digital health technologies for remote data acquisition covers selection, verification, validation, usability evaluation, risk management, and data retention.